RARE DISEASE
Benign schwannoma
Benign schwannoma
Benign schwannoma
Synonyms: Neurilemmoma, Neurilemoma, Peripheral fibroblastoma
Synonyms: Neurilemmoma, Neurilemoma, Peripheral fibroblastoma
Synonyms: Neurilemmoma, Neurilemoma, Peripheral fibroblastoma
Drug discovery
3
drugs
With orphan designations
Overview
Benign schwannomas are slow-growing, encapsulated tumors arising from Schwann cells of peripheral nerves, most commonly affecting the vestibular nerve (vestibular schwannoma) or spinal nerves [1][4][16]. Symptoms include localized pain, neurological deficits (numbness, weakness), and cranial nerve dysfunction (hearing loss, tinnitus, imbalance) [6][13][17]. Diagnosis relies on MRI/CT imaging and histopathological confirmation via biopsy [1][16]. Management options include surveillance for asymptomatic tumors, microsurgical resection for symptomatic cases, and stereotactic radiosurgery for inoperable tumors [1][13][19]. Prognosis is excellent post-resection, though rare malignant transformation (<2.5%) occurs, particularly in neurofibromatosis type 2 (NF2) or radiation-exposed patients [11][19][16].
Population
Peak incidence: 65–74 years (spinal) and 45–64 years (vestibular) [2][12].
Male predominance in spinal cases (IRR 0.86 vs. females) [2]; vestibular cases show slight female preference (52.6%) [7].
Associated with NF2 (bilateral vestibular tumors) and schwannomatosis (multiple peripheral tumors) [3][5][16].
Burden
Functional morbidity: Hearing loss (68.8%), facial palsy (82.2%), and balance disorders (91.8%) in vestibular cases [17].
Economic impact: Lifelong surveillance (MRI every 6–12 months) and surgical costs [1][13].
Malignant risk: <2.5% develop MPNSTs, particularly in NF2 or post-radiation cases [11][19].
Therapies
Categories: rare neoplastic diseases, rare neurological diseases
Research Papers
1,727 drug discovery papers about Benign schwannoma, with 2 first-in-class and 5 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,727 drug discovery papers about Benign schwannoma, with 2 first-in-class and 5 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-26 | Hybrid schwannoma-neurofibroma of the upper cervical spine: illustrative case and systematic review of spinal hybrid nerve sheath tumors.
Hybrid peripheral nerve sheath tumors (HPNSTs) are rare benign neoplasms characterized by the coexistence of multiple peripheral nerve sheath lineages, most commonly schwannoma, neurofibroma, and perineurioma. Although increasingly recognized as a distinct pathological entity, spinal involvement remains exceedingly uncommon, posing diagnostic and therapeutic challenges. A systematic review was conducted in accordance with PRISMA guidelines using PubMed, Scopus, and Web of Science from database inception to April 2026. Studies reporting histologically confirmed primary spinal HPNSTs were included. Demographic, clinical, radiological, histopathological, immunohistochemical, and outcome data were extracted and descriptively analyzed. A 25-year-old male presented with a 3-month history of progressive cervical and left shoulder pain accompanied by intermittent numbness. Magnetic resonance imaging revealed a dumbbell-shaped intradural extramedullary lesion at the C1-2 level with foraminal extension and cervical cord compression. Gross total microsurgical resection was achieved through a C1-C2 interlaminar microsurgical approach. Histopathological examination demonstrated a biphasic neoplasm composed of hypercellular schwannomatous nodules and hypocellular neurofibromatous areas within a collagenous and myxoid stroma. Immunohistochemistry revealed diffuse SOX10 positivity within the schwannian component and prominent CD34 reactivity in the neurofibromatous stroma, confirming a hybrid schwannoma-neurofibroma (WHO grade 1). The patient remained neurologically intact without recurrence at 20-month follow-up. Five eligible studies comprising nine spinal HPNST cases were identified. Schwannoma-perineurioma represented the predominant subtype (66.7%), whereas schwannoma-neurofibroma tumors accounted for (33.3%) of cases. Gross total resection was generally associated with favorable outcomes, while recurrence was rarely reported. Spinal HPNSTs are exceptionally rare lesions that remain difficult to diagnose preoperatively because of nonspecific radiological features. Definitive diagnosis relies on histopathological and immunohistochemical confirmation, whereas gross total resection appears to provide favorable outcomes.
2026-06-29 | Ancient Neurilemoma of the Lower Lip Mimicking Malignancy: A case report with Histopathologic Challenge
Neurilemoma, also known as Schwannoma, is a slowgrowing, benign tumor of the nerve sheath that is comparatively rare in the oral cavity. The “Ancient” variant of neurilemomas presents a substantial diagnostic problem, whereas regular neurilemomas exhibit a characteristic biphasic pattern. A 65-year-old woman with a hard, painless lump on his lower lip is the subject of this case report. Significant nuclear atypia and hyperchromasia were found during the initial histopathologic evaluation, which raised the possibility of a spindle cell sarcoma. Nonetheless, a diagnosis of Ancient Neurilemoma was confirmed by the robust S100 positive and lack of mitotic features. This case emphasizes how crucial it is to identify degenerative changes in order to prevent needless, drastic surgery. Bangladesh Journal of Medical Science Vol. 25. Supplementary Issue-2 (2026), Page : S359-S362
2026-06-17 | Repurposing anti-retroviral drugs to treat NF2-related tumours: a protocol for a phase 0 trial (RETREAT).
To date, there is no proven licensed systemic treatment for neurofibromatosis type 2 (NF2)-related schwannomatosis patients. There is a need for more effective, less toxic treatments and, as a rare disease, NF2 is often overlooked in targeted drug development. Subcutaneous schwannomas of the skin (CS) are common in the NF2 population.This trial involves the repurposing of medications already licensed for HIV-ritonavir and lopinavir (Kaletra and Norvir)-that have been shown to reduce tumour growth by reducing cell proliferation in human schwannoma and meningioma tumour cell cultures. The safety and tolerability of these drugs are already known, so they are safe candidates to trial in NF2 patients. This trial is an open-label, phase 0 design. A maximum of 16 participants diagnosed with NF2-related schwannomatosis will be enrolled in this study. Treatment duration is 30 days, with a 30-day follow-up. Biopsies and blood samples will be collected to assess whether the drugs reach the tumours and to analyse the tumour-cell response. The primary outcome is pharmacodynamic response, defined as a statistically significant decrease in biomarker activity in CS biopsy samples at day 30. The sample size calculation is based on the tissue biomarker response. The study was approved by an Ethics Committee (West of Scotland Research Ethics Service (23/WS/0178)), the Health Research Authority (HRA), the Medicines and Healthcare products Regulatory Authority (MHRA) and each of the participating NHS Trust's Research and Development departments. Following analysis of trial data, the trial results will be written up for publication in a peer-reviewed scientific journal and will be disseminated at conferences. ISRCTN10422213.
2026-06-12 | Medical Therapy for NF2-related Schwannomatosis: A Systematic Review of Current Evidence.
To synthesize the available evidence on medical therapies investigated for the management of NF2-related vestibular schwannomas (VS). Systematic review. Not applicable. NF2-related VS patients. Systemic medical therapies. Tumor control and hearing outcomes. Thirty studies met inclusion criteria: 18 investigated bevacizumab, 5 mTOR inhibitors, 5 tyrosine kinase inhibitors (TKIs), and 2 the vascular endothelial growth factor receptor (VEGFR) vaccine. Bevacizumab demonstrated the most consistent activity, with hearing improvement in up to 61% of patients, stable hearing in up to 84%, and tumor response in up to 60% (Level 4 evidence). Outcomes for mTOR inhibitors were variable, with 1 study stopped for futility, while others reported up to 100% hearing and tumor stability (Level 4 evidence). Five different TKIs showed hearing improvement rates ranging from 17 to 60% and tumor responses of 10 to 23.5% (Level 4 evidence). The VEGFR vaccine appeared safe and immunologically active, with radiologic and hearing improvement in one-third of patients (Level 4 evidence). Bevacizumab remains the most studied and clinically active systemic therapy for NF2-related VS, although evidence is largely nonrandomized. Other systemic therapies have demonstrated variable results in terms of hearing outcomes or tumor control. High-quality prospective and randomized controlled trials are needed to clarify efficacy, durability, and comparative effectiveness.
2026-05-25 | Multiple Peripheral Schwannomas of the Upper Limb – A Case Report
Schwannomas are the most common benign tumors of peripheral nerves, typically presenting as solitary, slow-growing lesions. Multiple schwannomas are rare and may indicate underlying syndromic conditions. We report a 68-year-old woman presenting with multiple upper limb nodules. MRI revealed well-defined lesions with T1 isointensity, T2 hyperintensity, and heterogeneous gadolinium enhancement. Surgical excision confirmed benign schwannoma. MRI is essential for evaluation, but histopathological confirmation remains mandatory.
2026-07-26 | Hybrid schwannoma-neurofibroma of the upper cervical spine: illustrative case and systematic review of spinal hybrid nerve sheath tumors.
Hybrid peripheral nerve sheath tumors (HPNSTs) are rare benign neoplasms characterized by the coexistence of multiple peripheral nerve sheath lineages, most commonly schwannoma, neurofibroma, and perineurioma. Although increasingly recognized as a distinct pathological entity, spinal involvement remains exceedingly uncommon, posing diagnostic and therapeutic challenges. A systematic review was conducted in accordance with PRISMA guidelines using PubMed, Scopus, and Web of Science from database inception to April 2026. Studies reporting histologically confirmed primary spinal HPNSTs were included. Demographic, clinical, radiological, histopathological, immunohistochemical, and outcome data were extracted and descriptively analyzed. A 25-year-old male presented with a 3-month history of progressive cervical and left shoulder pain accompanied by intermittent numbness. Magnetic resonance imaging revealed a dumbbell-shaped intradural extramedullary lesion at the C1-2 level with foraminal extension and cervical cord compression. Gross total microsurgical resection was achieved through a C1-C2 interlaminar microsurgical approach. Histopathological examination demonstrated a biphasic neoplasm composed of hypercellular schwannomatous nodules and hypocellular neurofibromatous areas within a collagenous and myxoid stroma. Immunohistochemistry revealed diffuse SOX10 positivity within the schwannian component and prominent CD34 reactivity in the neurofibromatous stroma, confirming a hybrid schwannoma-neurofibroma (WHO grade 1). The patient remained neurologically intact without recurrence at 20-month follow-up. Five eligible studies comprising nine spinal HPNST cases were identified. Schwannoma-perineurioma represented the predominant subtype (66.7%), whereas schwannoma-neurofibroma tumors accounted for (33.3%) of cases. Gross total resection was generally associated with favorable outcomes, while recurrence was rarely reported. Spinal HPNSTs are exceptionally rare lesions that remain difficult to diagnose preoperatively because of nonspecific radiological features. Definitive diagnosis relies on histopathological and immunohistochemical confirmation, whereas gross total resection appears to provide favorable outcomes.
2026-06-29 | Ancient Neurilemoma of the Lower Lip Mimicking Malignancy: A case report with Histopathologic Challenge
Neurilemoma, also known as Schwannoma, is a slowgrowing, benign tumor of the nerve sheath that is comparatively rare in the oral cavity. The “Ancient” variant of neurilemomas presents a substantial diagnostic problem, whereas regular neurilemomas exhibit a characteristic biphasic pattern. A 65-year-old woman with a hard, painless lump on his lower lip is the subject of this case report. Significant nuclear atypia and hyperchromasia were found during the initial histopathologic evaluation, which raised the possibility of a spindle cell sarcoma. Nonetheless, a diagnosis of Ancient Neurilemoma was confirmed by the robust S100 positive and lack of mitotic features. This case emphasizes how crucial it is to identify degenerative changes in order to prevent needless, drastic surgery. Bangladesh Journal of Medical Science Vol. 25. Supplementary Issue-2 (2026), Page : S359-S362
2026-06-17 | Repurposing anti-retroviral drugs to treat NF2-related tumours: a protocol for a phase 0 trial (RETREAT).
To date, there is no proven licensed systemic treatment for neurofibromatosis type 2 (NF2)-related schwannomatosis patients. There is a need for more effective, less toxic treatments and, as a rare disease, NF2 is often overlooked in targeted drug development. Subcutaneous schwannomas of the skin (CS) are common in the NF2 population.This trial involves the repurposing of medications already licensed for HIV-ritonavir and lopinavir (Kaletra and Norvir)-that have been shown to reduce tumour growth by reducing cell proliferation in human schwannoma and meningioma tumour cell cultures. The safety and tolerability of these drugs are already known, so they are safe candidates to trial in NF2 patients. This trial is an open-label, phase 0 design. A maximum of 16 participants diagnosed with NF2-related schwannomatosis will be enrolled in this study. Treatment duration is 30 days, with a 30-day follow-up. Biopsies and blood samples will be collected to assess whether the drugs reach the tumours and to analyse the tumour-cell response. The primary outcome is pharmacodynamic response, defined as a statistically significant decrease in biomarker activity in CS biopsy samples at day 30. The sample size calculation is based on the tissue biomarker response. The study was approved by an Ethics Committee (West of Scotland Research Ethics Service (23/WS/0178)), the Health Research Authority (HRA), the Medicines and Healthcare products Regulatory Authority (MHRA) and each of the participating NHS Trust's Research and Development departments. Following analysis of trial data, the trial results will be written up for publication in a peer-reviewed scientific journal and will be disseminated at conferences. ISRCTN10422213.
2026-06-12 | Medical Therapy for NF2-related Schwannomatosis: A Systematic Review of Current Evidence.
To synthesize the available evidence on medical therapies investigated for the management of NF2-related vestibular schwannomas (VS). Systematic review. Not applicable. NF2-related VS patients. Systemic medical therapies. Tumor control and hearing outcomes. Thirty studies met inclusion criteria: 18 investigated bevacizumab, 5 mTOR inhibitors, 5 tyrosine kinase inhibitors (TKIs), and 2 the vascular endothelial growth factor receptor (VEGFR) vaccine. Bevacizumab demonstrated the most consistent activity, with hearing improvement in up to 61% of patients, stable hearing in up to 84%, and tumor response in up to 60% (Level 4 evidence). Outcomes for mTOR inhibitors were variable, with 1 study stopped for futility, while others reported up to 100% hearing and tumor stability (Level 4 evidence). Five different TKIs showed hearing improvement rates ranging from 17 to 60% and tumor responses of 10 to 23.5% (Level 4 evidence). The VEGFR vaccine appeared safe and immunologically active, with radiologic and hearing improvement in one-third of patients (Level 4 evidence). Bevacizumab remains the most studied and clinically active systemic therapy for NF2-related VS, although evidence is largely nonrandomized. Other systemic therapies have demonstrated variable results in terms of hearing outcomes or tumor control. High-quality prospective and randomized controlled trials are needed to clarify efficacy, durability, and comparative effectiveness.
2026-05-25 | Multiple Peripheral Schwannomas of the Upper Limb – A Case Report
Schwannomas are the most common benign tumors of peripheral nerves, typically presenting as solitary, slow-growing lesions. Multiple schwannomas are rare and may indicate underlying syndromic conditions. We report a 68-year-old woman presenting with multiple upper limb nodules. MRI revealed well-defined lesions with T1 isointensity, T2 hyperintensity, and heterogeneous gadolinium enhancement. Surgical excision confirmed benign schwannoma. MRI is essential for evaluation, but histopathological confirmation remains mandatory.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
3 orphan drug designations for Benign schwannoma.
3 orphan drug designations for Benign schwannoma.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Salmonella enterica, subsp. enterica, serovar Typhimurium, strain YS1646, live | other | EMA | 2022-07-18 | — | Premier Research Group S.L. |
Live attenuated Salmonella enterica Serovar Typhimurium (S. Typhimurium) | gene therapies | FDA | 2022-05-10 | — | Mulberry Biotherapeutics, Inc. |
N-hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide | small molecules | EMA | 2012-06-06 | — | Propharma Group The Netherlands B.V. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.